NCT04485481View on ClinicalTrials.gov

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions
Safety Issues
Interventions
DRUG

ADX-914

Single dose from 0.1mg/kg to TBD

DRUG

Placebo

Matching single dose placebo

DRUG

ADX-914

Multiple dose from TBD to TBD

DRUG

Placebo

Matching multiple dose placebo

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors
lead

Q32 Bio Inc.

INDUSTRY

NCT04485481 - Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter